Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Bristol-Myers Squibb

Plavix continued to lead the way, as Abilify revenues slipped and other products showed growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 2Q10

2Q10 Revenues: $4.8 billion (+2%)

2Q10 Earnings: $927 million (-6%)

YTD Revenues: $9.6 billion (+7%)

YTD Earnings: $1.7 billion (+3%)

Comments: Plavix sales were $1.6 billion for 2Q10 (+6%) and $3.3 billion YTD (+11%). Abilify sales dropped 2% to $633 million in 2Q10 and were up 1% to $1.2 billion YTD. Several products showed strong growth in 2Q10, including Baraclude (+25% in 2Q10 to $223 million), Sprycel (+23% to $132 million), and Orencia (+20% to $178 million). R&D expenditure was flat for the quarter and YTD at $822 million and $1.7 billion, respectively. Onglyza posted $28 million in revenues.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters